Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Vaxart Inc - Key Facts 6

Vaxart Inc - Key Employees 7

Vaxart Inc - Key Employee Biographies 8

Vaxart Inc - Major Products and Services 9

Vaxart Inc - History 10

Vaxart Inc - Company Statement 12

Vaxart Inc - Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2 – Company Analysis 14

Company Overview 14

Vaxart Inc - Business Description 15

Vaxart Inc - Corporate Strategy 16

Vaxart Inc - SWOT Analysis 17

SWOT Analysis - Overview 17

Vaxart Inc - Strengths 17

Vaxart Inc - Weaknesses 18

Vaxart Inc - Opportunities 19

Vaxart Inc - Threats 20

Vaxart Inc - Key Competitors 21

Section 3 – Company Financial Ratios 22

Financial Ratios - Capital Market Ratios 22

Financial Ratios - Annual Ratios 23

Performance Chart 25

Financial Performance 25

Financial Ratios - Interim Ratios 26

Financial Ratios - Ratio Charts 27

Section 4 – Company’s Lifesciences Financial Deals and Alliances 28

Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28

Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29

Vaxart Inc, Recent Deals Summary 30

Section 5 – Company’s Recent Developments 31

Nov 28, 2018: Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018 31

Nov 09, 2018: Vaxart announces third quarter 2018 financial results and provides corporate update 32

Oct 04, 2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity 33

Oct 04, 2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity 35

Aug 09, 2018: Vaxart announces second quarter 2018 financial results and corporate update 36

May 15, 2018: Vaxart Announces First Quarter 2018 Financial Results and Corporate Update 37

Apr 19, 2018: Vaxart Appoints Brant Biehn As Senior Vice President, Commercial Operations 38

Apr 16, 2018: Vaxart to Present at Two Upcoming Medical Meetings 39

Nov 02, 2017: Aviragen Therapeutics Reports First Quarter of Fiscal Year 2018 Financial Results 40

Aug 31, 2017: Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results 41

Section 6 – Appendix 42

Methodology 42

Ratio Definitions 42

About GlobalData 46

Contact Us 46

Disclaimer 46

Vaxart Inc (AVIR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vaxart Inc (Vaxart) formerly Aviragen Therapeutics Inc is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary delivery platform. It is developing prophylactic vaccine candidates for a range of infectious diseases including norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company is also developing a therapeutic immune-oncology vaccine which targets cervical cancer and dysplasia caused by human papillomavirus (HPV). Vaxart’s vaccines are room temperature-stable tablets that can be stored and shipped without refrigeration. Vaxart is headquartered in San Francisco, California, the US.

Vaxart Inc Key Recent Developments

Nov 28,2018: Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
Nov 09,2018: Vaxart announces third quarter 2018 financial results and provides corporate update
Oct 04,2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Oct 04,2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
Oct 04,2018: New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company